I
Ironwood Pharmaceuticals
We are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients
At a glance
- Status
- Listed
- Founded
- 1998
- Headquarters
- Boston, United States
- Listing
- IPO 2010
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later4 investors entered at this stage
Polaris Partners
Morgan Stanley- WIWhitehead Institute
Notable Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former Ironwood Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
BSBloom ScienceEst. 2018
RMRepertoire Immune MedicinesEst. 2020
Bart HendersonUnited States
VCVets First ChoiceEst. 2010
David E. ShawUnited StatesGlobal footprint
team presence
across markets
Patents
52 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ironwood Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ironwood Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.